J7677 HCPCS Level II code: Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
J7677 is the HCPCS code for “Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7677Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
Short description: Revefenacin inh non-com 1mcg
HCPCS · United States
Medicare details
The indicators CMS publishes with J7677 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jul 1, 2019
Where J7677 sits
- 1J codesDrugs administered other than orally
- 2Active code J7677Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7677 mean?
J7677 is the HCPCS code for “Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7677?
CMS lists J7677’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7677
All J codesJ7667Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligramsJ7668Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligramsJ7669Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligramsJ7670Metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligramsJ7674Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mgJ7676Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mgJ7680Terbutaline sulfate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7681Terbutaline sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7682Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligramsJ7683Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7684Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7685Tobramycin, inhalation solution, compounded product, administered through dme, unit dose form, per 300 milligrams